Type 2 diabetes

1. 1

   Intestinal enzymes break digestible carbohydrates into absorbable sugars.

2. 2

   Glucose crosses the intestinal lining and enters portal blood traveling first to the liver.

3. 3

   The pancreas senses the rise, while gut-derived incretin hormones amplify meal-related insulin release.

4. 4

   The liver stores some glucose as glycogen; muscle uses or stores glucose according to energy demand.

A glucose measurement has meaning only in context: fasting, after a glucose load, after a usual meal, or as a longer-term HbA1c estimate. These tests answer different questions.

1. 1

   Beta cells release insulin in response to rising nutrients and incretin signals.

2. 2

   Insulin promotes GLUT4 movement to the surface of skeletal muscle and adipose cells.

3. 3

   In the liver, insulin favors glycogen synthesis and restrains gluconeogenesis and glycogen breakdown.

4. 4

   Between meals, lower insulin and relatively higher glucagon help the liver maintain circulating glucose.

Type 2 diabetes is not simply the absence of insulin. Many people initially have high insulin levels because the pancreas is compensating for resistance.

1. 1

   Insulin binds the insulin receptor, a receptor tyrosine kinase.

2. 2

   Receptor activation recruits insulin-receptor-substrate proteins.

3. 3

   The PI3K–AKT signaling pathway transmits much of the metabolic signal.

4. 4

   GLUT4-containing vesicles move to the membrane in muscle and adipose tissue, increasing glucose transport.

Insulin resistance can arise from disruption at several levels and differs between tissues. It is not one broken molecular switch shared identically by every person.

1. 1

   Intestinal cells release GLP-1 and GIP in response to nutrients.

2. 2

   Both can amplify insulin secretion when glucose is elevated.

3. 3

   GLP-1 also suppresses inappropriate glucagon, slows gastric emptying, and influences satiety.

4. 4

   DPP-4 rapidly breaks down native incretin hormones.

DPP-4 inhibitors slow incretin breakdown, while GLP-1 receptor agonists mimic stronger, longer signaling. These classes are related but are not interchangeable.

1. 1

   Reduced muscle insulin signaling lowers meal-related glucose disposal.

2. 2

   Hepatic insulin resistance permits continued gluconeogenesis and glycogen breakdown.

3. 3

   Adipose insulin resistance increases lipolysis and circulating fatty acids.

4. 4

   Ectopic fat, inflammation, genetics, sleep, medicines, aging, and other factors can influence this network.

Body size alone cannot diagnose insulin resistance or Type 2 diabetes. Risk reflects genetics, fat distribution, age, environment, medicines, pregnancy history, and other factors.

1. 1

   Insulin resistance raises the insulin demand required for glucose control.

2. 2

   Beta cells initially compensate through increased secretion.

3. 3

   Genetic susceptibility, glucotoxicity, lipotoxicity, islet stress, and other mechanisms can reduce beta-cell function.

4. 4

   Relative insulin deficiency becomes more important as the disease progresses.

Type 2 diabetes has no universally accepted numbered stages. Prediabetes, diagnosed diabetes, complications, and remission are clinical states—not a guaranteed one-way sequence.

1. 1

   Fasting glucose samples hepatic glucose regulation after an overnight fast.

2. 2

   The oral glucose tolerance test stresses the system and measures the 2-hour response.

3. 3

   HbA1c estimates longer-term glycemic exposure through glucose attachment to hemoglobin.

4. 4

   Without unequivocal hyperglycemia, diagnosis generally requires confirmatory abnormal testing.

HbA1c can be misleading when red-cell turnover or hemoglobin is altered. Clinicians choose and interpret tests in light of anemia, hemoglobin variants, pregnancy, kidney disease, medicines, acute illness, and symptoms.

1. 1

   Type 1 diabetes involves autoimmune beta-cell destruction and absolute insulin deficiency.

2. 2

   Slowly progressive autoimmune diabetes in adults may initially resemble Type 2 diabetes.

3. 3

   Single-gene defects can alter beta-cell function in monogenic diabetes.

4. 4

   Pancreatic injury, hormonal disease, and medicines can create secondary diabetes.

Unexpected weight loss, ketosis, rapid deterioration, a strong multigenerational pattern, pancreatic disease, or poor response to the expected treatment can prompt additional classification tests.

1. 1

   Metformin reduces hepatic glucose output through several linked cellular mechanisms.

2. 2

   Thiazolidinediones alter gene transcription through the nuclear receptor PPAR-gamma.

3. 3

   Neither class directly replaces insulin.

4. 4

   Kidney, liver, heart, fracture, fluid-retention, tolerability, and cost considerations affect selection.

Metformin remains widely used and is prominent in Indian workflows, but modern treatment is individualized. Cardiovascular disease, heart failure, kidney disease, weight goals, hypoglycemia risk, cost, and preferences can change the starting choice.

1. 1

   Sulfonylureas close beta-cell ATP-sensitive potassium channels and can cause glucose-independent insulin release.

2. 2

   DPP-4 inhibition prolongs endogenous GLP-1 and GIP signaling.

3. 3

   GLP-1–based therapy enhances glucose-dependent insulin release, suppresses glucagon, influences gastric emptying and satiety, and can reduce weight.

4. 4

   SGLT2 inhibition reduces proximal-tubule glucose reabsorption and has important heart and kidney benefits in selected people.

Hypoglycemia and weight gain are important with sulfonylureas; incretin therapies commonly cause gastrointestinal effects; SGLT2 inhibitors can cause genital infections, volume depletion, and rare ketoacidosis. This is why treatment cannot safely be chosen from mechanism alone.

1. 1

   Injected insulin supplements or replaces endogenous insulin action.

2. 2

   Basal insulin mainly restrains glucose production between meals and overnight.

3. 3

   Mealtime insulin addresses nutrient-related glucose rises.

4. 4

   Insulin plans require individualized dosing, monitoring, injection education, and hypoglycemia prevention.

Severe symptoms, ketosis, marked hyperglycemia, or acute metabolic decompensation require prompt professional assessment. This lesson intentionally does not provide dosing instructions.

1. 1

   Active muscle can increase glucose uptake through insulin-dependent and contraction-related pathways.

2. 2

   Weight reduction, when appropriate and achievable, can lower insulin resistance and may permit remission in some people.

3. 3

   Diet quality, carbohydrate amount and distribution, fiber, and total energy intake interact rather than acting as one forbidden-food list.

4. 4

   Blood-pressure, lipid, tobacco, sleep, and psychosocial care reduce risk beyond glucose alone.

Activity and meal changes can alter hypoglycemia risk when used with insulin or insulin-secretagogue medicines. Individual plans should account for kidney disease, pregnancy, frailty, eating disorders, and other conditions.

1. 1

   HbA1c reflects glycation over the life span of circulating red cells.

2. 2

   Capillary glucose provides a measurement at one moment.

3. 3

   Continuous glucose monitoring shows trends and time in ranges.

4. 4

   Urine albumin and estimated filtration assess different aspects of kidney injury and function.

Targets are individualized. Age, pregnancy, hypoglycemia risk, duration of diabetes, comorbidities, life expectancy, support, and treatment burden all influence what is appropriate.

1. 1

   Chronic hyperglycemia promotes glycation, oxidative stress, endothelial dysfunction, and altered microvascular signaling.

2. 2

   Hypertension and abnormal lipids add mechanical and atherosclerotic injury.

3. 3

   Glomerular injury can cause albumin leakage before filtration falls.

4. 4

   Sensory loss, altered foot loading, poor perfusion, and infection can combine in diabetic foot disease.

Screening seeks injury before symptoms appear. Sudden vision change, one-sided weakness, chest pressure, a cold or discolored limb, or a rapidly worsening foot wound needs urgent medical assessment.

1. 1

   Insufficient effective insulin allows glucose to rise and causes osmotic loss of water and electrolytes in urine.

2. 2

   Severe dehydration raises blood osmolality and can impair brain function.

3. 3

   More severe insulin deficiency permits fat breakdown and acidic ketone accumulation.

4. 4

   Infection, missed insulin, acute illness, myocardial infarction, some medicines, and newly presenting diabetes can precipitate a crisis.

Confusion, unusual drowsiness, repeated vomiting, deep or rapid breathing, severe weakness, inability to keep fluids down, or signs of major dehydration with high glucose are emergency warning signs. Seek local emergency care rather than relying on an educational app.